RT Journal Article SR Electronic T1 Expression of FAS-L Differs from Primary to Relapsed Low-grade Gliomas and Predicts Progression-free Survival JF Anticancer Research JO Anticancer Res FD International Institute of Anticancer Research SP 6639 OP 6648 VO 37 IS 12 A1 JAN-MICHAEL WERNER A1 SASKIA KUHL A1 PANTELIS STAVRINOU A1 GABRIELE RÖHN A1 BORIS KRISCHEK A1 TOBIAS BLAU A1 ROLAND GOLDBRUNNER A1 MARCO TIMMER YR 2017 UL http://ar.iiarjournals.org/content/37/12/6639.abstract AB Background/Aim: The tumor necrosis factor FAS is overexpressed in high-grade gliomas (HGG). Only little is known about FAS or FAS ligand (FAS-L) in low-grade gliomas (LGG). We explored FAS/FAS-L expression in LGG, focusing on differences in primary and relapsed LGG and on its prognostic value. Patients and Methods: A total of 133 glioma samples (73 LGG, 60 HGG) were collected. The LGG samples included 15 matched pairs of primary and relapsed tumors. RT-PCR was performed to measure FAS/FAS-L expression, using subunit A, flavoprotein variant (SDHA) as housekeeper. Clinical data included progression free- (PFS) and overall survival (OS). Results: LGG showed significantly lower FAS but higher FAS-L expression than HGG. The FAS-L expression was higher in primary compared to relapsed LGG and had a positive prognostic value concerning PFS (median 45.20 vs. 31.37 months). Conclusion: FAS-L could act as a prognostic marker and potential target in primary LGG.